The work presented here is part of a larger study to identify novel technologies and biomarkers for early Alzheimer disease (AD) detection and it focuses on evaluating the suitability of a new approach for early AD diagnosis by non-invasive methods. The purpose is to examine in a pilot study the potential of applying intelligent algorithms to speech features obtained from suspected patients in order to contribute to the improvement of diagnosis of AD and its degree of severity. In this sense, Artificial Neural Networks (ANN) have been used for the automatic classification of the two classes (AD and control subjects). Two human issues have been analyzed for feature selection: Spontaneous Speech and Emotional Response. Not only linear features but also non-linear ones, such as Fractal Dimension, have been explored. The approach is non invasive, low cost and without any side effects. Obtained experimental results were very satisfactory and promising for early diagnosis and classification of AD patients.

Alzheimer’s disease (AD) is the most prevalent form of progressive degenerative dementia; it has a high socioeconomic impact in Western countries. Therefore, it is one of the most active research areas today. Alzheimer’s disease is sometimes diagnosed by excluding other dementias, and definitive confirmation is only obtained through a postmortem study of the brain tissue of the patient. The work presented here is part of a larger study that aims to identify novel technologies and biomarkers for early AD detection, and it focuses on evaluating the suitability of a new approach for early diagnosis of AD by noninvasive methods. The purpose is to examine, in a pilot study, the potential of applying machine learning algorithms to speech features obtained from suspected Alzheimer’s disease sufferers in order to help diagnose this disease and determine its degree of severity. Two human capabilities relevant in communication have been analyzed for feature selection: spontaneous speech and emotional response. The experimental results obtained were very satisfactory and promising for the early diagnosis and classification of AD patients.

Alzheimer’s disease is characterized by a progressive and irreversible cognitive deterioration. In a previous stage, the so-called Mild Cognitive Impairment or cognitive loss appears. Nevertheless, this previous stage does not seem sufficiently severe to interfere in independent abilities of daily life, so it is usually diagnosed inappropriately. Thus, its detection is a crucial challenge to be addressed by medical specialists. This paper presents a novel proposal for such early diagnosis based on automatic analysis of speech and disfluencies, and Deep Learning methodologies. The proposed tools could be useful for supporting Mild Cognitive Impairment diagnosis. The Deep Learning approach includes Convolutional Neural Networks and nonlinear multifeature modeling. Additionally, an automatic hybrid methodology is used in order to select the most relevant features by means of nonparametric Mann–Whitney U test and Support Vector Machine Attribute evaluation.

Internet of things and smart cities are becoming a reality. Nowadays, more and more devices are interconnected and in order to deal with this new situation, data processing speeds are increasing to keep the pace. Smart devices like tablets and smartphones are accessible to a wide part of society in developed countries, and Internet connections for data exchange make it possible to handle large volumes of information in less time. This new reality has opened up the possibility of developing client-server architectures focused on clinical diagnosis in real time and at a very low cost. This paper illustrates the design and implementation of the ALZUMERIC system that is oriented to the diagnosis of Alzheimer’s disease (AD). It is a platform where the medical specialist can gather voice samples through non-invasive methods from patients with and without mild cognitive impairment (MCI), and the system automatically parameterizes the input signal to make a diagnose proposal. Although this type of impairment produces a cognitive loss, it is not severe enough to interfere with daily life. The present approach is based on the description of speech pathologies with regard to the following profiles: phonation, articulation, speech quality, analysis of the emotional response, language perception, and complex dynamics of the system. Privacy, confidentiality and information security have also been taken into consideration, as well as possible threats that the system could suffer, so this first prototype of services offered by ALZUMERIC has been targeted to a predetermined number of medical specialists.

Alzheimer’s disease is a progressive neurodegenerative disorder, the early detection of which is crucial for timely intervention and enrollment in clinical trials. However, the preclinical diagnosis of Alzheimer’s encounters difficulties with gold-standard methods. The current definitive diagnosis of Alzheimer’s still relies on expensive instrumentation and post-mortem histological examinations. Here, we explore label-free Raman spectroscopy with machine learning as an alternative to preclinical Alzheimer’s diagnosis. A special feature of this study is the inclusion of patient samples from different cohorts, sampled and measured in different years. To develop reliable classification models, partial least squares discriminant analysis in combination with variable selection methods identified discriminative molecules, including nucleic acids, amino acids, proteins, and carbohydrates such as taurine/hypotaurine and guanine, when applied to Raman spectra taken from dried samples of cerebrospinal fluid. The robustness of the model is remarkable, as the discriminative molecules could be identified in different cohorts and years. A unified model notably classifies preclinical Alzheimer’s, which is particularly surprising because of Raman spectroscopy’s high sensitivity regarding different measurement conditions. The presented results demonstrate the capability of Raman spectroscopy to detect preclinical Alzheimer’s disease for the first time and offer invaluable opportunities for future clinical applications and diagnostic methods.